

May 11, 2022

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sirs,

Sub: Compliance with Regulation 47(1)(b) of the SEBI Listing Regulations, 2015

Please find attached herewith copies of the newspaper publication of Audited Financial Results for the quarter and year ended March 31, 2022, published in Financial Express and Andhra Prabha on May 11, 2022 for your reference.

This is for your information and records.

Thanking you,

Yours faithfully,

For Neuland Laboratories Limited



Sarada Bhamidipati
Company Secretary

Encl : As above

NEULAND LABORATORIES LIMITED

(CIN : L85195TG1984PLC004393)

Regd. Office: 11th Floor (5th Office Level), Phoenix IVY Building,
Plot No. 573A-III, Road No 82, Jubilee Hills, Hyderabad - 500033



EXTRACT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2022

(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	Quarter Ended 31.03.2022	Quarter Ended 31.03.2021	Year Ended 31.03.2022	Year Ended 31.03.2021
1	Revenue from operations	25,587.25	24,470.47	95,107.66	93,691.31
2	Net profit for the period before tax	2,427.52	2,439.01	8,216.25	10,533.35
3	Net profit for the period after tax	2,178.07	1,729.26	6,382.20	8,063.07
4	Total comprehensive income for the period	1,994.69	1,580.93	5,789.21	7,906.60
5	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05	1,290.05
6	Other equity (excluding revaluation reserves) as shown in the audited balance sheet	82,676.14	77,271.83	82,676.14	77,271.83
7	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)				
	(a) Basic	16.97	13.48	49.74	62.85
	(b) Diluted	16.97	13.48	49.74	62.85

Note 1: The financial results for the quarter and year ended 31 March 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10 May 2022.

Note 2: Key Standalone Financial Information:

(Amount in lakhs of ₹)

Particulars	Quarter Ended 31.03.2022	Quarter Ended 31.03.2021	Year Ended 31.03.2022	Year Ended 31.03.2021
Revenue from operations	25,587.25	24,470.47	95,107.66	93,691.31
Net profit for the period before tax	2,412.17	2,431.59	8,173.98	10,496.21
Net profit for the period after tax	2,182.65	1,722.80	6,353.34	8,029.49

Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.neulandlabs.com

By Order of the Board
For and on behalf of the Board of Directors

Dr. D.R.Rao
Executive Chairman
(DIN 00107737)

Place: Hyderabad
Date : 10 May, 2022



బుధవారం 11 మే 2022

NEULAND LABORATORIES LIMITED

(CIN : L85195TG1984PLC004393)

Regd. Office: 11th Floor (5th Office Level), Phoenix IVY Building,
Plot No. 573A-III, Road No 82, Jubilee Hills, Hyderabad - 500033



EXTRACT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2022

(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	Quarter Ended 31.03.2022	Quarter Ended 31.03.2021	Year Ended 31.03.2022	Year Ended 31.03.2021
1	Revenue from operations	25,587.25	24,470.47	95,107.66	93,691.31
2	Net profit for the period before tax	2,427.52	2,439.01	8,216.25	10,533.35
3	Net profit for the period after tax	2,178.07	1,729.26	6,382.20	8,063.07
4	Total comprehensive income for the period	1,994.69	1,580.93	5,789.21	7,906.60
5	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05	1,290.05
6	Other equity (excluding revaluation reserves) as shown in the audited balance sheet	82,676.14	77,271.83	82,676.14	77,271.83
7	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)				
	(a) Basic	16.97	13.48	49.74	62.85
	(b) Diluted	16.97	13.48	49.74	62.85

Note 1: The financial results for the quarter and year ended 31 March 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10 May 2022.

Note 2: Key Standalone Financial Information:

(Amount in lakhs of ₹)

Particulars	Quarter Ended 31.03.2022	Quarter Ended 31.03.2021	Year Ended 31.03.2022	Year Ended 31.03.2021
Revenue from operations	25,587.25	24,470.47	95,107.66	93,691.31
Net profit for the period before tax	2,412.17	2,431.59	8,173.98	10,496.21
Net profit for the period after tax	2,182.65	1,722.80	6,353.34	8,029.49

Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.neulandlabs.com

By Order of the Board
For and on behalf of the Board of Directors

Dr. D.R.Rao
Executive Chairman
(DIN 00107737)

Place: Hyderabad
Date : 10 May, 2022